Virax Biolabs Group Limited

NasdaqCM:VRAX Stock Report

Market Cap: US$3.9m

Virax Biolabs Group Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

James Foster

Chief executive officer

US$490.7k

Total compensation

CEO salary percentage67.97%
CEO tenure4.1yrs
CEO ownership3.3%
Management average tenureno data
Board average tenure4.1yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 20

Virax stock soars 40% on launch of monkeypox rapid test kits

Virax Biolabs (NASDAQ:VRAX) said it began the distribution of monkeypox virus antigen rapid test kits which were launched in markets accepting the CE mark, such as the EU. The test kits are for use in point of care settings and can provide results in about 15 minutes, the company said in a Sept. 20 press release. Virax added that kits are used for in vitro qualitative detection of monkeypox virus antigen in throat swabs and skin exudates of humans by colloidal gold immunochromatography. "We are working diligently to distribute the kits as well as the previously announced Monkeypox and Varicella Zoster Viruses Real Time PCR Detection Kits into the hands of healthcare practitioners as quickly as possible," said Virax's Chairman and CEO James Foster. VRAX +40.08% to $3.46 premarket Sept. 20
Seeking Alpha • Jul 26

Virax Biolabs soars 37% on launch of real-time PCR test for monkeypox in Europe

Virax Biolabs (NASDAQ:VRAX) said it launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the recent Monkeypox outbreak. The London-based company said these diagnostic kits were now available in Europe and can be found by contacting its sales representatives. The test diagnosis Monkeypox and varicella-zoster viruses in human serum and lesion exudate specimens, providing a preliminary result, the company said in a July 26 press release. On July 23, the World Health Organization designated the current monkeypox outbreak a public health emergency of international concern — the agency's highest level of warning, previously issued for the COVID-19 and Ebola. The current outbreak has caused over 16,000 cases across 75 countries. As of July 25, there were 3,487 monkeypox/orthopoxvirus cases in the U.S., as per the U.S. CDC. Earlier in the week, Bavarian Nordic's smallpox vaccine Imvanex was approved in the EU for use in preventing monkeypox. VRAX +36.90% to $23.00 premarket July 26

CEO Compensation Analysis

How has James Foster's remuneration changed compared to Virax Biolabs Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$6m

Jun 30 2025n/an/a

-US$6m

Mar 31 2025US$491kUS$334k

-US$6m

Dec 31 2024n/an/a

-US$6m

Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024US$651kUS$325k

-US$7m

Dec 31 2023n/an/a

-US$7m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023US$2mUS$248k

-US$5m

Dec 31 2022n/an/a

-US$4m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022US$138kUS$138k

-US$2m

Dec 31 2021n/an/a

-US$1m

Sep 30 2021n/an/a

-US$860k

Jun 30 2021n/an/a

-US$755k

Mar 31 2021US$267kn/a

-US$651k

Compensation vs Market: James's total compensation ($USD490.69K) is about average for companies of similar size in the US market ($USD640.99K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Foster (41 yo)

4.1yrs
Tenure
US$490,692
Compensation

Mr. James Foster is co-founder of Virax Biolabs Group Limited and has been its Chief Executive Officer and serves as its Director & Chairman since May 2022 and serves as Principal Accounting Officer. From...

Board Members

NamePositionTenureCompensationOwnership
James Foster
Chairman4.1yrsUS$490.69k3.3%
$ 130.1k
Nigel McCracken
COO & Director2yrsUS$481.29k0.12%
$ 4.6k
Iain Miller
Independent Directorless than a yearno datano data
Nikolas Perrault
Member of Advisory Board4.9yrsno datano data
Gordon Powell
Member of Advisory Boardno datano datano data
Evan Norton
Independent Director4.1yrsUS$46.65k0.077%
$ 3.0k
Nelson Haight
Independent Director3.6yrsUS$46.65k0.077%
$ 3.0k
Assi Gol
Member of Advisory Board4.6yrsno datano data
Marc Frouin
Member of Advisory Board4.6yrsno datano data
Ailsa Snaith
Member of Advisory Boardno datano datano data
4.1yrs
Average Tenure
56yo
Average Age

Experienced Board: VRAX's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/05 09:19
End of Day Share Price 2026/06/05 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Virax Biolabs Group Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.